Journal article
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial
JA Cauley, L Norton, ME Lippman, S Eckert, KA Krueger, DW Purdie, J Farrerons, A Karasik, D Mellstrom, KW Ng, JJ Stepan, TJ Powles, M Morrow, A Costa, SL Silfen, EL Walls, H Schmitt, DB Muchmore, VC Jordan
Breast Cancer Research and Treatment | KLUWER ACADEMIC PUBL | Published : 2001
Abstract
Raloxifene, a selective estrogen receptor modulator approved for the prevention and treatment of postmenopausal osteoporosis, has shown a significant reduction in breast cancer incidence after 3 years in this placebo-controlled, randomized clinical trial in postmenopausal women with osteoporosis. This article includes results from an additional annual mammogram at 4 years and represents 3,004 additional patient-years of follow-up in this trial. Breast cancers were ascertained through annual screening mammograms and adjudicated by an independent oncology review board. A total of 7,705 women were enrolled in the 4-year trial: 2,576 received placebo, 2,557 raloxifene 60 mg/day, and 2,572 raloxi..
View full abstract